MEMatthias P. A. Ebert

Matthias P. A. Ebert

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Matthias P. A. Ebert has a total of 25 co-authors. Here are the top co-authors by number of shared publications:

  • Christoph Röcken

    Department of Pathology, University Hospital Schleswig-Holstein, Kiel, Germany

    2 shared publications
  • Jie Chen

    Department of Gastroenterology, Hepatology and Infectious Diseases, Otto‐von‐Guericke University, Magdeburg, Germany

    2 shared publications
  • Peter Malfertheiner

    Department of Gastroenterology, Hepatology and Infectious Diseases, Otto‐von‐Guericke University, Magdeburg, Germany

    2 shared publications
  • Albert Roessner

    Department of Pathology, Otto‐von‐Guericke University, Magdeburg, Germany

    1 shared publication
  • Claus Schäfer

    Department of Internal Medicine II, Klinikum Grosshadern, Ludwig Maximilians University, München, Germany

    1 shared publication
  • Constanze Kubisch

    Department of Internal Medicine II, Klinikum Grosshadern, Ludwig Maximilians University, München, Germany

    1 shared publication

Latest Publications

  • Protective role of heat shock protein 27 in gastric mucosal injury

    by Matthias Pa Ebert, Claus Schäfer, Jie Chen, Juliane Hoffmann, Ping Gu, Constanze Kubisch, Stacy Carl‐McGrath, Gerhard Treiber, Peter Malfertheiner, Christoph Röcken

    Heat shock protein 27 (HSP27) mediates cytoprotective effects through its function as a molecular chaperone and through the phosphorylation‐dependent stabilization of actin filaments. The role of HSP27 in gastric ulcer formation and healing is, however, unknown. The expression of HSP27 was studied in human gastric tissue specimens obtained from patients with gastric ulcers and from healthy Helicobacter pylori‐negative individuals, who received low‐dose aspirin, rofecoxib, and the combination in a prospective study. The susceptibility of the gastric mucosa to indomethacin‐induced lesions was further studied in transgenic mice overexpressing human HSP27 (TghuHSP27) and compared with wild‐type mice (Wt). The expression of HSP27, COX‐1, and COX‐2 was investigated in TghuHSP27 mice and Wt mice by immunohistochemistry and western blot analysis. While no specific changes in HSP27 expression were found following exposure of healthy human gastric mucosa to oral administration of aspirin or refocoxib, chronic gastric ulcers showed strong HSP27 expression at the ulcer base and margins. Here it was expressed by granulation tissue and regenerating surface epithelium. In TghuHSP27 mice, overexpression of HSP27 led to a significant decrease of indomethacin‐induced erosions and ulcers compared with Wt mice. COX‐1 and COX‐2 levels did not change. HSP27 is involved in chronic gastric ulcer repair mechanisms in humans, while overexpression of human HSP27 in gastric epithelial cells in mice reduces the susceptibility to non‐steroidal anti‐inflammatory drug (NSAID)‐induced gastric ulceration. This indicates that HSP27 expression is critical for mucosal protection in the stomach. Copyright © 2005 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.


  • Overexpression of cathepsin B in gastric cancer identified by proteome analysis

    by Matthias P. A. Ebert, Sabine Krüger, Marie‐Laure Fogeron, Stephanie Lamer, Jie Chen, Matthias Pross, Hans‐Ulrich Schulz, Hermann Lage, Steffen Heim, Albert Roessner, et al.

    We aimed to validate an analytical approach based on proteomics on gastric cancer specimens for the identification of new putative diagnostic or prognostic markers. Primary screening was performed on gastrectomy specimens obtained from ten consecutive patients with gastric cancer. Gastric epithelial cells were obtained with an epithelial cell enrichment technique, homogenized and then separated by two‐dimensional polyacrylamide gel electrophoresis (2‐D PAGE). The differential protein expression pattern was verified stepwise by Western blotting and immunohistochemistry on samples from 28 and 46 cancer patients, respectively. The putative clinical applicability and prognostic use were tested by an enzyme‐linked immunoabsorbent assay on serum samples obtained from 149 cancer patients. One hundred‐ninety‐one differentially expressed protein spots were found by 2‐D PAGE and identified by mass spectrometry, including cathepsin B, which was over‐expressed in six (60%) patients. Western blotting confirmed that the active form of cathepsin B is over‐expressed, while immunohistochemistry showed strong cytoplasmic staining in cancer tissues of 45 (98%) patients. The serum level of cathepsin B was increased in patients with gastric cancer compared to healthy controls (P = 0.0026) and correlated with T‐category and the presence of distant metastases (P < 0.05). Serum levels above 129 pmol·L−1 were associated with a reduced survival rate (P = 0.0297). Proteome analysis is a valuable tool for the identification of prognostic markers in gastric cancer: Increased cathepsin B serum levels are associated with advanced tumor stages and progressive disease, which enables the classification of some gastric cancer patients into a subgroup that should undergo aggressive therapy.


  • Expression of carbonic anhydrase IX in human pancreatic cancer

    by M. Juhász, J. Chen, U. Lendeckel, U. Kellner, H.‐U. Kasper, Z. Tulassay, S. Pastorekova, P. Malfertheiner, M. P. A. Ebert

    Summary: Background : Carbonic anhydrase IX has been linked to cancer development and progression.Aim : To analyse carbonic anhydrase IX expression and anhydrase inhibition in pancreatic cancer and to correlate these findings with p53 expression and microvessel density.Materials and methods : Seventy‐seven pancreatic cancers were examined (43 males, 34 females; mean age, 64 years). The anti‐carbonic anhydrase IX M75 antibody was used for immunohistochemistry and Western blot analysis. Microvessels were visualized using the anti‐CD34 antibody, and p53 expression in cancer cells was assessed with a specific anti‐p53 antibody. Quantitative polymerase chain reaction was performed in order to assess carbonic anhydrase IX mRNA levels in the pancreas. Furthermore, pancreatic cancer cell lines were treated with acetazolamide, a carbonic anhydrase inhibitor.Results : In the normal pancreas, carbonic anhydrase IX immunoreactivity was observed at the basolateral membrane of ductal cells in 24 cases (31%). Carbonic anhydrase IX expression was found at the membrane and in the cytoplasm of pancreatic cancer cells in 16 pancreatic cancers (21%). Carbonic anhydrase IX expression was independent of the localization, stage, size, metastases and differentiation of the tumour. p53 expression was significantly more frequent in poorly differentiated cancers (P = 0.0323); however, p53 expression and microvessel density were independent of carbonic anhydrase IX expression. Overall, carbonic anhydrase IX expression was not altered in pancreatic cancers vs. adjacent normal pancreatic tissue as assessed by Western blot and quantitative polymerase chain reaction analysis. However, incubation of pancreatic cancer cell lines with acetazolamide led to a significant inhibition of cell proliferation in AsPC‐1 and PANC‐1 pancreatic cancer cells.Conclusion : Carbonic anhydrase IX expression is observed in both ductal epithelial and cancer cells of the pancreas. Although the expression of carbonic anhydrase IX in pancreatic cancer is not associated with angiogenesis or advanced disease, it may well be a target for carbo‐anhydrase inhibitors in a subset of pancreatic cancers.